NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, October 29th. Stockholders of record on Friday, November 8th will be given a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, November 7th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) posted its earnings results on Tuesday, October, 29th. The biotechnology company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.14. The biotechnology company earned $183.24 million during the quarter, compared to the consensus estimate of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.98 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 brokers have issued 12 month target prices for BIO-TECHNE's shares. Their forecasts range from $179.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $231.50 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

News headlines about TECH stock have been trending positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIO-TECHNE earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 418,000 shares, an increase of 12.7% from the December 15th total of 370,900 shares. Based on an average daily trading volume, of 121,200 shares, the short-interest ratio is currently 3.4 days. Currently, 1.1% of the company's shares are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), AbbVie (ABBV), Global Medical REIT (GMRE), Amgen (AMGN), Gilead Sciences (GILD), NVIDIA (NVDA), General Electric (GE), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Ionis Pharmaceuticals (IONS).

BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.02%), Summit Creek Advisors LLC (0.22%), Nisa Investment Advisors LLC (0.05%), Assenagon Asset Management S.A. (0.04%), Tributary Capital Management LLC (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, State of Alaska Department of Revenue, Tributary Capital Management LLC, Summit Creek Advisors LLC and We Are One Seven LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tocqueville Asset Management L.P., Chicago Capital LLC, First National Bank of Omaha, Nisa Investment Advisors LLC, Diversified Trust Co, Huntington National Bank and Argus Investors Counsel Inc.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $220.61.

BIO-TECHNE has a market capitalization of $8.41 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]